SUSTAIN 3: Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes

Date: 
December, 2017

December 2017. In this 56-week, phase 3, open-label, parallel-group, controlled trial, 813 patients with type 2 diabetes (T2D) were randomized 1:1 to add-on therapy with semaglutide 1.0 mg or exenatide extended-release (ER) 2.0 mg. The primary endpoint was change in A1C levels from baseline (8.3%). At study end, A1C was reduced by 1.5% with semaglutide and 0.9% with exenatide ER (P<0.0001 for noninferiority and superiority). Additionally, significantly more patients treated with semaglutide vs exenatide ER achieved A1C levels <7.0% (67% vs 40%, respectively), and mean body weight was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (P<0.0001). Both treatments had similar safety profiles, with gastrointestinal adverse events more common in semaglutide than exenatide ER and injection-site reactions more common with exenatide ER than semaglutide. The investigators concluded that semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight over 56 weeks of treatment in patients with T2D. Follow this link to read the full study abstract.